Kiora Pharmaceuticals (NASDAQ:KPRX) Rating Reiterated by HC Wainwright

Kiora Pharmaceuticals (NASDAQ:KPRX)‘s stock had its “buy” rating reiterated by investment analysts at HC Wainwright in a report issued on Wednesday, Benzinga reports.

Kiora Pharmaceuticals Trading Down 0.0 %

Shares of KPRX stock traded down $0.00 during trading hours on Wednesday, reaching $0.60. The company’s stock had a trading volume of 198,743 shares, compared to its average volume of 1,625,697. Kiora Pharmaceuticals has a fifty-two week low of $0.46 and a fifty-two week high of $5.25. The firm’s 50 day simple moving average is $0.64 and its 200-day simple moving average is $0.59.

Institutional Investors Weigh In On Kiora Pharmaceuticals

A number of hedge funds have recently made changes to their positions in the stock. Boothbay Fund Management LLC bought a new position in shares of Kiora Pharmaceuticals in the 4th quarter valued at $40,000. Dimensional Fund Advisors LP bought a new position in Kiora Pharmaceuticals in the first quarter valued at about $41,000. Acadian Asset Management LLC acquired a new stake in shares of Kiora Pharmaceuticals during the first quarter valued at about $70,000. Citadel Advisors LLC bought a new stake in shares of Kiora Pharmaceuticals during the fourth quarter worth about $49,000. Finally, Renaissance Technologies LLC bought a new position in Kiora Pharmaceuticals in the 1st quarter valued at approximately $58,000. 76.97% of the stock is currently owned by institutional investors and hedge funds.

About Kiora Pharmaceuticals

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.